Deutsche Bank Ag\ Kinnate Biopharma Inc. Transaction History

Deutsche Bank Ag\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $42,019 - $123,352	-18,034 Reduced 13.57%	114,846 $347,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $6,677 - $15,401	1,930 Added 1.47%	132,880 $830,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $1,030 - $2,389	196 Added 0.15%	130,950 $798,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $19,236 - $30,747	-1,951 Reduced 1.47%	130,754 $1.56 Million
Q2 2022 Aug 11, 2022	BUY	$7.43 - $13.0 $4,955 - $8,671	667 Added 0.51%	132,705 $1.67 Million
Q1 2022 May 13, 2022	SELL	$7.73 - $17.99 $12,816 - $29,827	-1,658 Reduced 1.24%	132,038 $1.49 Million
Q4 2021 Feb 11, 2022	BUY	$16.5 - $25.48 $13,695 - $21,148	830 Added 0.62%	133,696 $2.37 Million
Q3 2021 Nov 04, 2021	BUY	$17.81 - $24.87 $116,744 - $163,022	6,555 Added 5.19%	132,866 $3.06 Million
Q2 2021 Aug 11, 2021	BUY	$22.19 - $31.55 $2.2 Million - $3.13 Million	99,184 Added 365.63%	126,311 $2.94 Million
Q1 2021 May 13, 2021	BUY	$26.99 - $40.0 $732,157 - $1.09 Million	27,127 New	27,127 $845,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.